Tema Etfs LLC Makes New $1.23 Million Investment in Genmab A/S (NASDAQ:GMAB)

Tema Etfs LLC bought a new position in Genmab A/S (NASDAQ:GMAB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 58,935 shares of the company’s stock, valued at approximately $1,230,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GMAB. EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the period. Barclays PLC grew its stake in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after buying an additional 2,285 shares during the period. Cromwell Holdings LLC grew its stake in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after buying an additional 2,496 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Genmab A/S during the 4th quarter valued at $60,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Up 1.2%

NASDAQ:GMAB opened at $19.88 on Friday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.06. The firm has a market capitalization of $12.75 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 2.65 and a beta of 1.04. The firm’s fifty day simple moving average is $19.74 and its 200 day simple moving average is $20.75.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. On average, analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

GMAB has been the subject of several research reports. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.